Background: It is well known that antibiotic use is the main driver for the increas-
of deaths due to infections caused by resistant bacteria will reach 10 million lives each year. 3 Following this, modern medicine can be set back to a time where simple infections again will be lethal. Around 90% of antibiotics are prescribed in primary care, 4 thus making general practice a crucial area for interventions aimed at reducing unnecessary use of antibiotics. In general practice, most lower respiratory tract infections (LRTI) are mild and require no antibiotic treatment. In fact, only about 13% of patients with the diagnosis of pneumonia in general practice have a radiologically verifiable pneumonia. 5 Furthermore, many patients are recommended to complete an antibiotic treatment even if their symptoms have resolved; the rationale behind these recommendations are not evidence-based, but mainly based on traditions. 1, 6 Use, misuse and overuse of antibiotics are the main drivers for the selection of resistance bacteria. Reduced prescribing rate and shorter duration of an antibiotic course can reduce exposure to antibiotics and hereby curbing antibiotic resistance.
The duration of antibiotic treatment of community-acquired pneumonia (CAP) has long been discussed in the scientific community due to lacking evidence of the current regimen, that is 7-10 days of treatment. Consequently, several studies have recently been conducted to investigate the effects of a shorter duration of antibiotic treatment.
The aim of this review was to investigate whether the effectiveness of a short-course antibiotic is comparable to a longer course of antibiotics in adults with CAP, and to assess whether the duration of an antibiotic course will influence the development of resistant bacteria.
| MATERIALS AND METHODS

| Literature search
A literature search was performed to identify randomized, controlled trials comparing short-vs long-course antibiotic treatments for CAP. Trials published before 23 April 2018 in English were identified in PubMed and EMBASE. The search was based on the following terms: "community-acquired pneumonia," the MeSH term "community-acquired infections" with the following subheadings: "therapy" and "drug therapy" and a combination of the following words: antibiotic*, short/shorter-course, long/longer-course, duration and antibiotic duration. A complete search string is available from the authors on request.
| Selection of articles
Only randomized, controlled trials were included. A trial was considered eligible for inclusion if it (a) included adults (18+ years) diagnosed with CAP, (b) compared a short-course antibiotic treatment with a longer course, and (c) if patients exclusively were treated at outpatient clinics.
Furthermore, the following exclusion criteria were applied: (a) studies testing individualized treatment, and (b) studies including patients with comorbidity such as chronic lung disease or lung cancer.
| Outcome measures
A short-course antibiotic treatment was defined as 5 days of treatment, and a long-course antibiotic treatment was defined as 7+ days of treatment.
The following outcomes were reported:
1. Clinical success, defined as if clinical symptoms and signs associated with the pneumonia were resolved. 2. Microbiological efficacy, defined as decrease pre-treatment compared to post-treatment, in the amount of bacterial colonies or eradication of bacterial cultures. 3. Patient safety, defined as the reporting of adverse events, which were classified as either related, possibly related or unrelated, and/or mild, moderate or severe. 4. Development of resistant bacteria (any reporting on resistant bacteria).
| Quality assessment
The quality of the included randomized, controlled trials was assessed by the Jadad criteria. 7 The trials were evaluated in seven items, the first five items can obtain +1 point and the last 2 items can be given −1 point, which makes the highest score in a total of five the best assessment (Table 4 ). The points were awarded for randomization, blinding, description of withdrawals and drop-outs.
| RESULTS
| Study characteristics
The searches in PubMed and EMBASE resulted in 276 and 19 potential studies, respectively. Most trials (N = 125) were excluded as they compared the effects of different types of antibiotics, 38 trials were excluded because they included children, and an additional 29 trials were excluded as they were not about CAP. Six studies were included in this literature review. The selection process is described in detail in Figure 1 .
Four of the included trials randomized the population right from the start of the trial, [8] [9] [10] [11] and two studies did not randomize the study population until after five days of treatment, and only if a treatment effect was observed 12, 13 ( Table 1) . Table 2 presents an overview of all study results from the six included trials.
T A B L E 1
| Type and dose of antibiotics
The included studies tested various antibiotics such as levofloxacin, gemifloxacin, amoxicillin and cefuroxime. Three trials used different doses of antibiotics in the short-and longcourse treatment groups, respectively, with the highest dose of antibiotics used in the short-course treatment groups. 8, 9, 11 In another two studies, the short-course treatment group and long-course treatment group received the same dose of antibiotics. 10, 13 In the study by Uranga et al, it was only stated that antibiotic treatments were according to local guidelines; consequently, it is unknown what type of antibiotic was used, and in which doses they were prescribed.
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| Clinical success
In the three studies using different dosage of antibiotics but same type of antibiotic, 750 mg levofloxacin short-course regimen (5 days) vs 500 mg levofloxacin (median 10 days), all had high clinical success rates and there was no statistically significant difference between the two groups. The clinical success rates were 90%-94% in patients treated with short-course levofloxacin and 91%-96% in patients treated with long-course levofloxacin. 8, 9, 11 In the three studies, where the intervention group and control group received the same dose of antibiotics, there was likewise a high clinical success rate with no statistically significant difference between the short-course and long-course treatment groups. The clinical success rates were 88%-95% in patients treated with short-course antibiotics and 88%-92% in patients treated with long-course antibiotics. 10, 13 In the study by Uranga et al 12 , in which the local guidelines determined the dose of antibiotic, the clinical success rate at follow-up was 92.7% and 94.4%, respectively, in the short-course treatment group (5 days) and long-course treatment group (median 10 days) (P = 0,54). Overall, a clinical success rate of 91%-94% was observed when antibiotics were given for 7-14 days (long-course). Similarly, a clinical success rate of 86.9%-95.0% was observed when antibiotic courses were prescribed for 5 days (short-course). Table 3 provides an overview of pathogens identified in patients diagnosed with CAP in the six included trials. Three studies included the microbiological eradication as a secondary efficacy parameter. [8] [9] [10] The microbiological efficacy was based on the results of cultures taken pre-and post-treatment. Zhao, T. 8 and Zhao, X. 9 found a bacterial eradication rate of 100% in both the short-course and long-course treatment groups. File et al 10 examined the eradication rates of Streptococcus pneumoniae and identified a small nonsignificant difference in the eradication efficacy rate at follow-up, with 100% for those treated for 5 days (short-course) and 95% for those treated with antibiotics for 7+ days (longcourse), (Table 2) .
| Microbiological efficacy
| Patient safety evaluation
All six studies reported on patient safety outcomes (Table 2 ). In the studies by Uranga et al and Dunbar et al, no significant differences in adverse events were observed between the groups by day 30. 11, 12 In one study, 55% of patients had experienced an adverse event in the 750-mg levofloxacin group (short-course), and 49% of patients had reported an adverse events in the 500-mg levofloxacin group (longcourse). 9 These adverse events were considered drug-related but with no significant difference. 9 One study showed that the incidence of adverse events was low and the proportion of discontinuations due to adverse events was 1.2% and 2% for the short-course and long-course treatment groups, respectively. 10 In the study by El Moussaoui et al 13 , 11% in the short-course treatment group compared with 21% in the longcourse treatment group reported mild adverse events during or at the end of treatment periods (Table 2) .
S aureus
Of the five studies reporting on adverse events, none of them demonstrated statistically significant differences in the number of adverse events, notwithstanding antibiotics were given for a shorter or longer period.
| Antibiotic resistance
None of the included trials reported on the impact of the duration of an antibiotic course on the development of resistant bacteria. [8] [9] [10] [11] 13 
| Jadad score
The quality of the included trials varied and ranged from two to four in Jadad score-a detailed overview of the quality assessments is available in Table 4 .
Three points were given to three of the studies, 8, 10, 12 one trial obtained two points 9 and the rest obtained four points. 11, 13 All of the included studies obtained points for being a randomized, controlled trial and for the description of withdrawal. None of the studies were deducted a point for inappropriate randomization or blinding.
| DISCUSSION
| Main findings
Adults treated for CAP had similar clinical cure rates when given a short-course of antibiotics (5 days) compared to those receiving a longer course (7 + days). Also, almost identical bacterial eradication rates were demonstrated regardless of treatment duration, and no difference in the reporting of adverse events was found. Importantly, there was an absence of evidence on the impact of treatment duration on the development of antibiotic resistance.
| Strengths and limitations
This literature review has summarized the evidence from the relatively few trials reporting on short-vs long-course antibiotic treatment for CAP. The included trials differ in certain aspects (Tables 1 and 5 ). The differences include various randomization procedures, diverse study Only six randomized, controlled trials were included in this review and the risk of a type 2 error, that is rejecting that there is a difference between choosing a shorter treatment period compared to a longer treatment period is present. This possible difference in effectiveness between the treatment duration is important to identify due to the risk of severe complications associated with CAP. With this in mind, more trials testing optimal treatment durations are highly needed to be able to provide solid evidence for optimal treatment durations for patients diagnosed with CAP.
T A B L E 5 Article overview of relapses, withdrawals and limitations
Study (year) Relapses Patients withdrawals/mortality Limitations
Uranga A et al (2016) 12 Readmission by day 30 was significantly more common in the control group than in the intervention group 9 vs. 2, P = 0.02
Before randomization, 227 patients did not meet the selection criteria. Thirteen patients were later excluded for protocol violation. In addition, 16 were unavailable for the late follow-up. For one of these patients, no data were found, and it is not known if this is alive. Several other limitations have to be kept in mind when interpreting the results of this literature review. Firstly, none of the included trials provided any information about the effect of the duration of the antibiotic courses on the development of resistant bacteria. Consequently, we were not able to report on this outcome, however, it seems plausible that by minimizing the days of antibiotic treatment, the risk of antimicrobial resistance can be reduced.
Secondly, none of the included trials provided sufficient data to report on the comparative effectiveness of short vs long courses of antibiotics for rare outcomes associated with CAP, such as hospitalization or deaths.
Furthermore, the various treatment durations were not assessed in accordance with the severity of the infections (mild, moderate, severe), or perhaps more importantly the aetiology of the pneumonia. For example, pneumonia caused by Legionella pneumophila is recommended antibiotic treatment for two to three weeks, compared with seven days for pneumonia caused by Streptococcus pneumonia.
14 Some of the included trials used different doses of antibiotic, with a higher dosage in the short-course duration group compared with the dosage in the long-course duration group. This decreases internal comparability in this review, and instead raises the question whether it is the duration or total amount of antibiotics that matter to the success rate. In one study, patients were first treated with intravenous treatment, in contrast to a complete oral course (El Moussaoui 2006). This approach is not usual care in most general practices and consequently influences the generalizability of these findings.
The quality of the included trials was moderate with Jadad scores of two to four, primarily three. However, this score only indicates something about the methodological quality of the trials and nothing about generalizability or the quality of the results in the included studies. For example, most studies were conducted in middle-and high-income countries and with great variation in the study population. There were few data on comparative effectiveness of short and long courses of antibiotics in low-income countries, where baseline risks, immunization rates, complication rates and access to antibiotic treatment may differ substantially from middle-or high-income countries.
| Comparison with other studies
In the fight against the increasing problems with resistant bacteria, the optimal length of antibiotic treatment for CAP is being massively investigated these years. 1, 15, 16 A metaanalysis from 2007 found no significant differences between short-course (5 days) and long-course (7 + days) antibiotic regimens for the treatment of mild to moderate CAP with respect to clinical success, mortality, bacteriological success and adverse events. 15 A more recent review from 2017
showed similar clinical cure rates when given shorter courses of antibiotics compared to those receiving longer courses. In this review, a shorter course of antibiotics was also associated with lower rates of adverse events than longer courses of antibiotic. 1 This present literature review did not include children; however, a study by Agarwal G et al 16 demonstrated equivalent efficacy of three days vs five days of antibiotic treatment of pneumonia in children. Importantly, a newly published review from 2018 by López-Alcalde J et al did not identify any randomized, controlled trials studying a short course of antibiotic compared to a longer course, with the same type of antibiotic and with the same daily dosage, for CAP in adult outpatients. 17 
| CONCLUSION
Despite the above-mentioned differences in the designs of the included studies and the limitations of this literature review, all of the included trials demonstrated a similar clinical effect in patients treated with either a short or long antibiotic course. However, only six trials were included and more trials investigating the optimal antibiotic treatment duration of CAP are warranted. Preferably, these trials should compare treatments with the same type of antibiotic, and same dose, and test antibiotics commonly used in most European countries (eg phenoxymethylpenicillin or amoxicillin). Also, these trials should involve both children and adults and importantly not only focus on efficacy outcomes, but also on adverse events including the development of resistant bacteria.
